Search

Your selection

Clear all

Filter by category

Filter by content type

Filter by content year

News

Dynavax Enters Exclusive License Agreement for Vaxart’s Novel Oral COVID-19 Vaccine Program

November 5, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025

October 20, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

October 8, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Announces Withdrawal of Reverse Stock Split Proposal

September 19, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Appoints W. Mark Watson as Lead Independent Director

September 17, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

September 10, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … regarding clinical results and trial data, including their design, and the timing of such trials and of receiving and … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by …
News

Vaxart Announces Adjournment of Special Meeting of Stockholders

September 8, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025

September 3, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors

September 2, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Granted Extension by Nasdaq to Regain Compliance

August 29, 2025 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
Scroll to Top